Alert detail
FDA Approval: IBRANCE (PALBOCICLIB) — Type 3 - New Dosage Form
Policy ID: FDA-NDA212436Specialty: Multi-specialtyAdded: 6/27/2026Effective: November 1, 2019federal register
What changed
New FDA drug approval. Coverage and billing pathway depend on the FDA label and applicable Medicare LCDs/NCDs — for very recent approvals the label may not be posted yet. Verify against the FDA label and current coverage policy before billing.
Who’s affected: Multi-specialty billing teams · Effective: November 1, 2019
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.